Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effect of weight loss rate on liver steatosis, steatohepatitis, fibrosis and cardiovascular risk at different stages before and after bariatric surgery. The investigators also aim to study the short-term effect of bariatric surgery on gastric cholecystokinin levels before and 10 days after the bariatric surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NAFLD after SG | 26 patients with NAFLD undergoing sleeve gastrectomy (SG). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sleeve gastrectomy | Procedure | An intra-operative liver biopsy was performed in 20 patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline liver steatosis, steatohepatitis and fibrosis at different stages after bariatric surgery, measured by non-invasive measurements as described below. | Measurements to be performed to assess liver disease stage at baseline and at 8-12 days and 12, 24 and 48 weeks after surgery:
| Baseline is defined as three weeks to one month before surgery. Different stages to compare to baseline are as following: 8-12 days and 12, 24 and 48 weeks after surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| Change of postoperative cardiovascular risk compared to baseline. | Patients will undergo brachial artery flow-mediated dilation (FMD) test (surrogate marker for endothelial function and cardiovascular risk). | Baseline is defined as three weeks to one month before surgery. Change will be assessed 6-12 months after surgery. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Alcohol drinking > 140g/week
Presence of hepatitis B or C or HIV
Known liver disease such as:
Not provided
Not provided
26 diabetic patients with NAFLD (diagnosed by ultra sound) undergoing sleeve gastrectomy (SG) at Surgery C department at Sheba Medical Center, Israel.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ziv Ben-Ari, Prof | Director Liver Disease Center, Sheba Medical Center, Tel-Hashomer, Israel | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Liver Disease Center, Sheba Medical Center, Tel-Hashomer | Ramat Gan | 52621 | Israel |
Not provided
| ID | Term |
|---|---|
| D065626 | Non-alcoholic Fatty Liver Disease |
| D009765 | Obesity |
| D015431 | Weight Loss |
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D050177 | Overweight |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood, Liver tissue
| Change in cholecystokinin levels before and after the surgery. |
In addition, gastric cholecystokinin levels will be measured from the removed stomach tissue. |
| Baseline levels of cholecystokinin at 1-2 days before surgery compared to 8-12 days after surgery. |
| D044343 |
| Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001836 | Body Weight Changes |